Friday, June 1, 2018

Dapagliflozin drives HbA1c, SBP, and weight down in DERIVE

The use of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin in patients with type 2 diabetes (T2D) and moderate renal impairment provides benefits beyond glucose lowering, with no new safety signals, in phase III DERIVE* study.

No comments:

Post a Comment